The AACR Annual Meeting program covers the latest discoveries across the spectrum of cancer research - from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy - and highlights the work of the best minds in research and medicine from institutions all over the world. 

Lytix Biopharma will attend AACR (American Association of Cancer Research) with the following 3 posters:

__________________________________________________________________________________

Sunday March 31st; 1:00 PM – 5:00 PM

“A phase I study of the oncolytic peptide LTX-315 generates de novo T-cell responses and clinical benefit in patients with advanced sarcoma”

Session Title: Phase I Clinical Trials: Part 1

Exhibit Hall B, Poster Section 16; Poster nr CT010

__________________________________________________________________________________

Monday April 1st; 8:00 AM – 12:00 PM

“A phase I study of the oncolytic peptide LTX-315 generates de novo T-cell responses and clinical benefit in patients with advanced melanoma”

Session Title: Phase I Clinical Trials: Part 2

Exhibit Hall B, Poster Section 17; Poster nr CT069

__________________________________________________________________________________

Tuesday April 2nd; 8:00 AM – 12:00 PM

“LTX-401 as a novel antitumor and immunotherapeutic agent in an experimental liver cancer model”

Session: Immunology

Session Title: Novel Immunomodulatory agents 1

Exhibit Hall B, Poster Section 25; Poster nr 3274